– моментальные уведомления о рынке акций
– моментальные уведомления о рынке акций
– Strong year-over-year net sales growth, driven by new product introductions and International sales –– Company raises lower end of full-year 2022 financial guidance range –
SAN DIEGO, May 4, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2022.
First Quarter 2022
"I am pleased with our results during the first quarter, which exceeded our expectations," said Chris Barry, chief executive officer of NuVasive. "Despite COVID-19 and macro-economic pressure in the first half of the quarter, our performance reflects the strong health of our business and positions us well for continued growth. Looking ahead to the remainder of the year, we expect our novel technology to drive further differentiation with our surgeon partners. Led by the X360 and C360 systems—including the Simplify Cervical Disc—and the Pulse platform, we are committed to executing on our near- and long-term strategic plan to drive value for our stakeholders."
First Quarter 2022 ResultsNuVasive reported total net sales of $290.8 million, a 7.2% increase as reported and a 9.1% increase on a constant currency basis, compared to $271.2 million in the prior year period. First quarter 2022 total net sales were driven by higher procedure volume in the U.S., and strong international performance.
For the first quarter of 2022, GAAP gross profit was $211.7 million, compared to $199.4 million in the prior year period. GAAP gross margin was 72.8%, compared to 73.5% in the prior year period. On a non-GAAP basis, gross profit was $212.2 million, compared to $199.6 million in the prior year period. Non-GAAP gross margin was 73.0%, compared to 73.6% in the prior year period.
The Company reported GAAP net income of $19.2 million, or diluted earnings per share of $0.35, compared to a GAAP net loss of ($7.5) million, or diluted loss per share of ($0.15) in the prior year period. On a non-GAAP basis, the Company reported net income of $28.2 million, or diluted earnings per share of $0.54, compared to non-GAAP net income of $19.0 million, or diluted earnings per share of $0.37 in the prior year period.
Cash and cash equivalents were $205.3 million as of March 31, 2022.
Updated Annual Financial Guidance for 2022
The Company updated its financial guidance for the full year 2022 based on the current business outlook to raise the lower end of its guidance range for net sales growth:
Prior guidance range ** |
Current guidance range ** |
|||
GAAP |
Non-GAAP |
GAAP |
Non-GAAP |
|
Net sales growth (reported)* |
5.0%-8.0% |
5.0%-8.0% |
6.0%-8.0% |
6.0%-8.0% |
Net sales growth (constant currency)* |
6.0%-9.0% |
7.5%-9.5% |
||
Operating margin |
6.7%-8.2% |
13.0%-14.5% |
6.3%-7.8% |
13.0%-14.5% |
Diluted earnings per share |
$0.71-$1.01 |
$2.05-$2.35 |
$1.05-$1.35*** |
$2.15-$2.45 |
* Reflects expectations for net sales growth in 2022 compared to 2021. Net sales growth on a constant currency basis excludes year over year currency fluctuations, which the Company currently expects to create a negative impact of approximately 150 basis points in 2022. |
** Prior guidance reflects the range provided February 23, 2022. Current guidance reflects the range provided May 4, 2022. |
*** Reflects updated expectations for the impact on diluted EPS of applying the if-converted method to the Company's convertible notes. Additionally, includes the impact of net unrealized foreign currency exchange gains incurred as of March 31, 2022, and does not assume future net unrealized gains or losses related to foreign currency exchange rates. |
A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this press release and on the Investor Relations section of our website.
Conference Call and WebcastThe Company will hold a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the first quarter of 2022. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call and supplemental financial information of our first quarter 2022 financial results will be available on the Investor Relations page of our website at www.nuvasive.com. An audio replay of the call will be available until May 11, 2022. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13728729. In addition, the webcast will be archived on NuVasive's website.
About NuVasiveNuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.
Reconciliation of GAAP to Non-GAAP InformationManagement uses certain non-GAAP financial measures such as non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating margin, non-GAAP net income (loss), and non-GAAP diluted earnings (loss) per share. These non-GAAP financial measures exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring charges, non-cash purchase accounting adjustments, inventory charges associated with product withdrawals, certain foreign currency impacts and related items in connection with acquisitions, investments and divestitures, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, gains and losses from changes in fair value of derivatives, non-cash interest expense (excluding debt issuance cost) and other significant one-time items. Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring charges, non-cash purchase accounting adjustments, inventory charges associated with product withdrawals, certain foreign currency impacts and related items in connection with acquisitions, investments and divestitures, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, gains and losses from changes in fair value of derivatives and other significant one-time items.
Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below in the financial tables accompanying this press release are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measure.
Forward-Looking StatementsNuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. In addition, this news release contains selected financial results from the first quarter 2022, as well as projections for 2022 financial guidance and expectations regarding longer-term financial performance. The Company's results for the first quarter of 2022 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. In addition, the Company's projections for 2022 financial guidance and expectations regarding longer-term financial performance represent initial estimates, and are subject to the risk of being inaccurate because of the preliminary nature of the forecasts, the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, the impact of the COVID-19 pandemic on the Company's business and financial results; the Company's ability to maintain operations to support its customers and patients in the near-term and to capitalize on future growth opportunities; risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
NuVasive, Inc. |
||||
Consolidated Statements of Operations |
||||
(in thousands, except per share data) |
||||
Three Months Ended March 31, |
||||
(unaudited) |
2022 |
2021 |
||
Net sales: |
||||
Products |
$ 265,973 |
$ 245,451 |
||
Services |
24,789 |
25,798 |
||
Total net sales |
290,762 |
271,249 |
||
Cost of sales (excluding below amortization of intangible assets): |
||||
Products |
57,183 |
53,302 |
||
Services |
21,914 |
18,509 |
||
Total cost of sales |
79,097 |
71,811 |
||
Gross profit |
211,665 |
199,438 |
||
Operating expenses: |
||||
Selling, general and administrative |
160,281 |
145,954 |
||
Research and development |
23,358 |
22,224 |
||
Amortization of intangible assets |
13,032 |
13,337 |
||
Business transition costs |
3,060 |
5,584 |
||
Total operating expenses |
199,731 |
187,099 |
||
Interest and other income (expense), net: |
||||
Interest income |
43 |
87 |
||
Interest expense |
(4,379) |
(8,030) |
||
Other income (expense), net |
16,244 |
(12,526) |
||
Total interest and other income (expense), net |
11,908 |
(20,469) |
||
Income (loss) before income taxes |
23,842 |
(8,130) |
||
Income tax (expense) benefit |
(4,641) |
620 |
||
Consolidated net income (loss) |
$ 19,201 |
$ (7,510) |
||
Net income (loss) per share: |
||||
Basic |
$ 0.37 |
$ (0.15) |
||
Diluted |
$ 0.35 |
$ (0.15) |
||
Weighted average shares outstanding: |
||||
Basic |
51,829 |
51,379 |
||
Diluted |
62,579 |
51,379 |
||
NuVasive, Inc. |
||||
Consolidated Balance Sheets |
||||
(in thousands, except par value data) |
||||
March 31, 2022 |
December 31, 2021 |
|||
ASSETS |
(Unaudited) |
|||
Current assets: |
||||
Cash and cash equivalents |
$ 205,312 |
$ 246,091 |
||
Accounts receivable, net of allowances of $20,707 and $21,064, respectively |
231,425 |
214,398 |
||
Inventory, net |
324,403 |
315,845 |
||
Prepaid income taxes |
5,536 |
5,425 |
||
Prepaid expenses and other current assets |
25,538 |
20,665 |
||
Total current assets |
792,214 |
802,424 |
||
Property and equipment, net |
313,689 |
303,664 |
||
Intangible assets, net |
233,301 |
242,675 |
||
Goodwill |
636,703 |
633,467 |
||
Operating lease right-of-use assets |
100,656 |
102,987 |
||
Deferred tax assets |
61,294 |
48,003 |
||
Restricted cash and investments |
1,494 |
1,494 |
||
Other assets |
21,150 |
19,361 |
||
Total assets |
$ 2,160,501 |
$ 2,154,075 |
||
LIABILITIES AND EQUITY |
||||
Current liabilities: |
||||
Accounts payable and accrued liabilities |
$ 115,674 |
$ 115,614 |
||
Contingent consideration liabilities |
66,054 |
7,986 |
||
Accrued payroll and related expenses |
55,848 |
66,596 |
||
Operating lease liabilities |
10,043 |
9,867 |
||
Income tax liabilities |
1,110 |
828 |
||
Total current liabilities |
248,729 |
200,891 |
||
Long-term senior convertible notes |
886,793 |
884,984 |
||
Deferred tax liabilities |
12,807 |
3,049 |
||
Operating lease liabilities |
109,093 |
111,592 |
||
Contingent consideration liabilities |
73,762 |
139,824 |
||
Other long-term liabilities |
17,396 |
18,528 |
||
Commitments and contingencies |
||||
Stockholders' equity: |
||||
Preferred stock, $0.001 par value; 5,000 shares authorized, none outstanding |
— |
— |
||
Common stock, $0.001 par value; 150,000 shares authorized at March 31, 2022 and |
63 |
63 |
||
Additional paid-in capital |
1,441,783 |
1,434,976 |
||
Accumulated other comprehensive loss |
(11,741) |
(7,792) |
||
Retained earnings |
64,909 |
45,708 |
||
Treasury stock at cost; 6,798 shares and 6,700 shares at March 31, 2022 and |
(683,093) |
(677,748) |
||
Total equity |
811,921 |
795,207 |
||
Total liabilities and equity |
$ 2,160,501 |
$ 2,154,075 |
||
NuVasive, Inc. |
||||
Consolidated Statements of Cash Flows |
||||
(in thousands) |
||||
Three Months Ended March 31, |
||||
(unaudited) |
2022 |
2021 |
||
Operating activities: |
||||
Consolidated net income (loss) |
$ 19,201 |
$ (7,510) |
||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||
Depreciation and amortization |
36,801 |
36,432 |
||
Deferred income taxes |
(3,891) |
(3,535) |
||
Amortization of non-cash interest |
1,963 |
2,660 |
||
Stock-based compensation |
6,807 |
7,709 |
||
Net (gain) loss from foreign currency adjustments |
(15,988) |
12,547 |
||
Reserves on current assets |
(1,864) |
4,002 |
||
Other non-cash adjustments |
1,365 |
6,397 |
||
Changes in operating assets and liabilities, net of effects from acquisitions: |
||||
Accounts receivable |
(17,216) |
(1,544) |
||
Inventory |
(3,215) |
(12,464) |
||
Prepaid expenses and other current assets |
805 |
(2,057) |
||
Accounts payable and accrued liabilities |
(7,956) |
(5,663) |
||
Accrued payroll and related expenses |
(10,491) |
(4,271) |
||
Income taxes |
218 |
(1,064) |
||
Net cash provided by operating activities |
6,539 |
31,639 |
||
Investing activities: |
||||
Acquisition of Simplify Medical, net of cash acquired |
— |
(149,408) |
||
Purchases of intangible assets |
— |
(1,200) |
||
Purchases of property and equipment |
(33,223) |
(25,070) |
||
Proceeds from sales of marketable securities |
— |
127,023 |
||
Proceeds from maturities of marketable securities |
— |
46,000 |
||
Other investing activities |
(947) |
— |
||
Net cash used in investing activities |
(34,170) |
(2,655) |
||
Financing activities: |
||||
Payment of contingent consideration |
(6,839) |
(3) |
||
Purchases of treasury stock |
(5,345) |
(55) |
||
Payments upon settlement of senior convertible notes |
— |
(649,426) |
||
Other financing activities |
(521) |
(341) |
||
Net cash used in financing activities |
(12,705) |
(649,825) |
||
Effect of exchange rate changes on cash |
(443) |
(2,171) |
||
Decrease in cash, cash equivalents and restricted cash |
(40,779) |
(623,012) |
||
Cash, cash equivalents and restricted cash at beginning of period |
247,585 |
858,363 |
||
Cash, cash equivalents and restricted cash at end of period |
$ 206,806 |
$ 235,351 |
||
For the Three Months Ended March 31, 2022 |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(Unaudited - in thousands, except per share data) |
|||||||
Gross Profit |
Operating |
Net Income |
Diluted |
Diluted |
Net Income |
||
Reported GAAP |
$ 211,665 |
$ 11,934 |
$ 19,201 |
$ 0.35 |
62,579 |
$ 19,201 |
|
% of net sales |
72.8% |
4.1% |
|||||
Non-cash purchase accounting adjustments on acquisitions1 |
557 |
557 |
557 |
557 |
|||
Amortization of intangible assets |
13,032 |
13,032 |
|||||
Litigation related expenses and settlements2 |
3,201 |
3,201 |
3,201 |
||||
Business transition costs3 |
3,060 |
3,060 |
3,060 |
||||
European medical device regulation4 |
2,191 |
2,191 |
2,191 |
||||
Non-cash acquisition-related foreign currency impacts5 |
(9,318) |
(9,318) |
|||||
Tax effect of adjustments6 |
(3,768) |
||||||
Interest expense/(income), net |
4,336 |
||||||
Income tax expense |
4,641 |
||||||
Depreciation and amortization |
36,801 |
||||||
Non-cash stock-based compensation |
6,807 |
||||||
Adjusted Non-GAAP |
$ 212,222 |
$ 33,975 |
$ 28,156 |
$ 0.54 |
52,410 |
$ 71,477 |
|
% of net sales |
73.0% |
11.7% |
24.6% |
||||
1 |
Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized |
||||||
2 |
Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property. |
||||||
3 |
Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party |
||||||
4 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical |
||||||
5 |
Represents non-cash adjustments to acquisition-related intercompany balances and contingent consideration liabilities held in a foreign currency. |
||||||
6 |
Represents the impact from tax affecting the adjustments above at their statutory tax rate. |
||||||
7 |
GAAP diluted EPS includes the dilutive impact of applying the if-converted method to the Company's convertible notes. Adjusted non-GAAP diluted WASO |
||||||
For the Three Months Ended March 31, 2021 |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(Unaudited - in thousands, except per share data) |
|||||||
Gross |
Operating |
Net (Loss) |
Diluted |
Diluted |
Net (Loss) to |
||
Reported GAAP |
$ 199,438 |
$ 12,339 |
$ (7,510) |
$ (0.15) |
51,379 |
$ (7,510) |
|
% of net sales |
73.5% |
4.5% |
|||||
Non-cash purchase accounting adjustments on acquisitions1 |
186 |
186 |
186 |
186 |
|||
Amortization of intangible assets |
13,337 |
13,337 |
|||||
Litigation related expenses and settlements2 |
1,961 |
1,961 |
1,961 |
||||
Business transition costs3 |
5,584 |
5,584 |
5,584 |
||||
European medical device regulation4 |
1,875 |
1,875 |
1,875 |
||||
Non-cash acquisition-related foreign currency impacts5 |
9,848 |
9,848 |
|||||
Tax effect of adjustments6 |
(6,251) |
||||||
Interest expense/(income), net |
7,943 |
||||||
Income tax benefit |
(620) |
||||||
Depreciation and amortization |
36,432 |
||||||
Non-cash stock-based compensation |
7,709 |
||||||
Adjusted Non-GAAP |
$ 199,624 |
$ 35,282 |
$ 19,030 |
$ 0.37 |
52,069 |
$ 63,408 |
|
% of net sales |
73.6% |
13.0% |
23.4% |
||||
1 |
Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized |
||||||
2 |
Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property. |
||||||
3 |
Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party |
||||||
4 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical |
||||||
5 |
Represents non-cash adjustments to acquisition-related intercompany balances and contingent consideration liabilities held in a foreign currency. |
||||||
6 |
Represents the impact from tax affecting the adjustments above at their statutory tax rate. |
||||||
7 |
GAAP diluted EPS includes the dilutive impact of applying the if-converted method to the Company's convertible notes. Adjusted non-GAAP diluted WASO |
||||||
Full Year 2022 Financial Guidance |
|||||||
Reconciliation of GAAP to Non-GAAP EPS |
|||||||
2022 Guidance Range1, 2 |
|||||||
2021 Actuals1 |
Prior |
Current |
|||||
GAAP diluted earnings (loss) per share |
$(1.24) |
$0.71-1.01 |
$1.05-1.35 |
||||
Impact of dilution3 |
0.02 |
~0.15 |
~0.05 |
||||
Amortization of intangible assets |
1.10 |
~1.05 |
~1.00 |
||||
European medical device regulation4 |
0.16 |
~0.30 |
~0.30 |
||||
Inventory charges associated with product withdrawal5 |
0.27 |
- |
- |
||||
Other6 |
1.83 |
~0.14 |
~0.05 |
||||
Tax effect of adjustments7 |
(0.45) |
~(0.30) |
~(0.30) |
||||
Non-GAAP diluted earnings per share |
$1.68 |
$2.05-2.35 |
$2.15-2.45 |
||||
1 |
Data has been intentionally rounded and may not sum. |
||||||
2 |
Prior guidance reflects the range provided February 23, 2022. Current guidance reflects the range provided May 4, 2022. |
||||||
3 |
GAAP diluted EPS includes the dilutive impact of applying the if-converted method to the Company's convertible notes. Adjusted non-GAAP diluted |
||||||
4 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European |
||||||
5 |
Represents charges for inventory write-offs associated with the Company's product withdrawals. During the third quarter of 2021, the Company made a |
||||||
6 |
Includes costs primarily associated with litigation related expenses and settlements, non-cash acquisition-related foreign currency impacts, non-cash |
||||||
7 |
Represents the impact from tax affecting the adjustments above at their statutory tax rate. |
||||||
Full Year 2022 Financial Guidance |
||||||||
Reconciliation of GAAP to Non-GAAP Operating Margin % |
||||||||
2022 Guidance Range1, 2 |
||||||||
2021 Actuals1 |
Prior |
Current |
||||||
GAAP Operating Margin % |
(1.1%) |
6.7%-8.2% |
6.3%-7.8% |
|||||
Amortization of intangible assets |
5.0% |
~4.5% |
~4.4% |
|||||
European medical device regulation3 |
0.7% |
~1.3% |
~1.3% |
|||||
Inventory charges associated with product withdrawal4 |
1.3% |
- |
- |
|||||
Other 5 |
6.8% |
~0.5% |
~1.0% |
|||||
Non-GAAP Operating Margin % |
12.8% |
13.0%-14.5% |
13.0%-14.5% |
|||||
1 |
Data has been intentionally rounded and may not sum. |
|||||||
2 |
Prior guidance reflects the range provided February 23, 2022. Current guidance reflects the range provided May 4, 2022. |
|||||||
3 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with |
|||||||
4 |
Represents charges for inventory write-offs associated with the Company's product withdrawals. During the third quarter of 2021, the |
|||||||
5 |
Includes costs primarily associated with litigation related expenses and settlements, non-cash purchase accounting adjustments on |
|||||||
SOURCE NuVasive, Inc.
– Значительный рост чистых продаж в годовом исчислении, обусловленный внедрением новых продуктов и международными продажами –– Компания повысила нижнюю границу диапазона финансовых прогнозов на весь 2022 год –
САН-ДИЕГО, 4 мая 2022 г. /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), лидер в области инноваций в области технологий для позвоночника, специализирующийся на преобразовании хирургии позвоночника с помощью минимально разрушительных, процедурно интегрированных решений, сегодня объявил финансовые результаты за квартал, закончившийся 31 марта 2022 года.
Первый квартал 2022 года
"Я доволен нашими результатами в первом квартале, которые превзошли наши ожидания", - сказал Крис Барри, главный исполнительный директор NuVasive. "Несмотря на COVID-19 и макроэкономическое давление в первой половине квартала, наши результаты отражают крепкое здоровье нашего бизнеса и дают нам хорошие позиции для дальнейшего роста. Заглядывая в будущее до конца года, мы ожидаем, что наша новая технология будет способствовать дальнейшей дифференциации среди наших партнеров-хирургов. Во главе с системами X360 и C360, включая Simplify Cervical Disc, и платформой Pulse мы стремимся выполнять наш краткосрочный и долгосрочный стратегический план по повышению ценности для наших заинтересованных сторон ".
Результаты первого квартала 2022 года NuVasive сообщила об общем объеме чистых продаж в размере 290,8 млн долларов, что на 7,2% больше, чем сообщалось, и на 9,1% больше в постоянной валюте по сравнению с 271,2 млн долларов в предыдущем году. Общий объем чистых продаж в первом квартале 2022 года был обусловлен увеличением объема операций в США и высокими международными показателями.
За первый квартал 2022 года валовая прибыль по GAAP составила 211,7 млн долларов по сравнению с 199,4 млн долларов за аналогичный период предыдущего года. Валовая прибыль по ОПБУ составила 72,8% по сравнению с 73,5% в предыдущем году. На основе без учета GAAP валовая прибыль составила 212,2 млн долларов США по сравнению с 199,6 млн долларов США за аналогичный период предыдущего года. Валовая прибыль без учета GAAP составила 73,0% по сравнению с 73,6% в предыдущем году.
Компания сообщила о чистой прибыли по ОПБУ в размере 19,2 млн долларов США, или разводненной прибыли на акцию в размере 0,35 доллара США, по сравнению с чистым убытком по ОПБУ в размере (7,5 млн долларов США), или разводненным убытком на акцию в размере (0,15 доллара США) за предыдущий год. На основе без учета GAAP Компания сообщила о чистой прибыли в размере 28,2 млн долларов США, или разводненной прибыли на акцию в размере 0,54 доллара США, по сравнению с чистой прибылью без учета GAAP в размере 19,0 млн долларов США, или разводненной прибылью на акцию в размере 0,37 доллара США за предыдущий год.
Денежные средства и их эквиваленты по состоянию на 31 марта 2022 года составили 205,3 миллиона долларов.
Обновленные Годовые финансовые рекомендации на 2022 год
Компания обновила свои финансовые прогнозы на весь 2022 год, основываясь на текущих перспективах бизнеса, чтобы повысить нижнюю границу своего диапазона прогнозов по росту чистых продаж:
Prior guidance range ** |
Current guidance range ** |
|||
GAAP |
Non-GAAP |
GAAP |
Non-GAAP |
|
Net sales growth (reported)* |
5.0%-8.0% |
5.0%-8.0% |
6.0%-8.0% |
6.0%-8.0% |
Net sales growth (constant currency)* |
6.0%-9.0% |
7.5%-9.5% |
||
Operating margin |
6.7%-8.2% |
13.0%-14.5% |
6.3%-7.8% |
13.0%-14.5% |
Diluted earnings per share |
$0.71-$1.01 |
$2.05-$2.35 |
$1.05-$1.35*** |
$2.15-$2.45 |
* Reflects expectations for net sales growth in 2022 compared to 2021. Net sales growth on a constant currency basis excludes year over year currency fluctuations, which the Company currently expects to create a negative impact of approximately 150 basis points in 2022. |
** Prior guidance reflects the range provided February 23, 2022. Current guidance reflects the range provided May 4, 2022. |
*** Reflects updated expectations for the impact on diluted EPS of applying the if-converted method to the Company's convertible notes. Additionally, includes the impact of net unrealized foreign currency exchange gains incurred as of March 31, 2022, and does not assume future net unrealized gains or losses related to foreign currency exchange rates. |
Полную сверку финансовых показателей GAAP с финансовыми показателями, не относящимися к GAAP, можно найти в таблицах этого пресс-релиза и в разделе по связям с инвесторами нашего веб-сайта.
Конференц-связь и веб-трансляция Компания проведет телефонную конференцию в среду, 4 мая 2022 года, в 16:30 вечера по восточному времени / 1:30 вечера по североамериканскому времени, чтобы обсудить результаты своих финансовых показателей за первый квартал 2022 года. Набираемые номера: 1-877-407-9039 для внутренних абонентов и 1-201-689-8470 для международных абонентов. Прямая трансляция телефонной конференции и дополнительная финансовая информация о наших финансовых результатах за первый квартал 2022 года будут доступны на странице по связям с инвесторами нашего веб-сайта по адресу www.NuVasive.com . Аудиозапись разговора будет доступна до 11 мая 2022 года. Номера повторного набора: 1-844-512-2921 для внутренних абонентов и 1-412-317-6671 для международных абонентов. Пожалуйста, используйте pin-код: 13728729. Кроме того, веб-трансляция будет заархивирована на веб-сайте NuVasive.
О компании NuVasiveNuVasive, Inc. (NASDAQ: NUVA) - лидер в области инноваций в области технологий для позвоночника, цель которого - трансформировать хирургию, улучшить уход и изменить жизнь. Менее инвазивные, процедурно интегрированные хирургические решения компании разработаны для обеспечения воспроизводимых и клинически подтвержденных результатов. Обширный процедурный портфель компании включает инструменты для хирургического доступа, спинномозговые имплантаты, системы фиксации, биологические препараты, программное обеспечение для планирования операций, решения для навигации и визуализации, системы имплантатов с магнитной регулировкой для позвоночника и ортопедии, а также технологии и услуги интраоперационного нейромониторинга. С чистым объемом продаж более 1 миллиарда долларов NuVasive работает в более чем 50 странах, обслуживая хирургов, больницы и пациентов. Для получения дополнительной информации, пожалуйста, посетите www.NuVasive.com .
Сверка GAAP с информацией, не относящейся к GAAP, В управлении используются определенные финансовые показатели, не относящиеся к GAAP, такие как валовая прибыль, не относящаяся к GAAP, валовая прибыль, не относящаяся к GAAP, операционные расходы, не относящиеся к GAAP, операционная маржа, не относящаяся к GAAP, чистая прибыль (убыток), не относящаяся к GAAP, и разводненная прибыль (убыток), не относящаяся к GAAP, на поделиться. Эти финансовые показатели, не относящиеся к GAAP, исключают амортизацию нематериальных активов, затраты на переход к бизнесу, приобретенные исследования и разработки в процессе производства, единовременные расходы на реструктуризацию, корректировки учета неденежных покупок, расходы на складские запасы, связанные с изъятием продукции, определенное влияние иностранной валюты и связанные статьи в связи с приобретениями, инвестициями и продажами, определенные судебные издержки и расчеты, определенные расходы на регулирование европейского медицинского оборудования, прибыли и убытки от стратегических инвестиций, прибыли и убытки от изменений справедливой стоимости производных финансовых инструментов, неденежные процентные расходы (за исключением затрат на выпуск долговых обязательств) и другие существенные единовременные статьи. Руководство также использует определенные меры, не относящиеся к GAAP, которые предназначены для исключения влияния колебаний валютных курсов. Постоянная валюта измерения использует обменный курс, который исключает колебания при расчете показателей финансовых показателей. Компания также использует такие показатели, как свободный денежный поток, который представляет собой денежный поток от операций за вычетом денежных средств, использованных при приобретении и отчуждении капитала. Кроме того, Компания использует скорректированный показатель EBITDA, который представляет прибыль до вычета процентов, налогов, износа и амортизации и исключает влияние компенсации на основе запасов, затрат на переход бизнеса, приобретенных исследований и разработок в процессе производства, единовременных расходов на реструктуризацию, корректировок учета безналичных покупок, расходов на складские запасы, связанных с продуктом изъятия, определенные изменения в иностранной валюте и связанные с ними статьи в связи с приобретениями, инвестициями и отчуждениями, определенные судебные расходы и расчеты, определенные расходы на регулирование европейского медицинского оборудования, прибыли и убытки от стратегических инвестиций, прибыли и убытки от изменений справедливой стоимости производных финансовых инструментов и другие существенные единовременные статьи.
Руководство рассчитывает финансовые показатели, не относящиеся к GAAP, представленные в этом отчете о прибылях и убытках, исключая эти затраты, и использует эти финансовые показатели, не относящиеся к GAAP, чтобы позволить ему проводить дальнейший и более последовательный анализ финансовых показателей своих основных бизнес-операций от периода к периоду. Руководство считает, что предоставление инвесторам этих показателей, не относящихся к GAAP, дает им дополнительную информацию, позволяющую им оценивать, точно так же, как руководство оценивает текущую и будущую непрерывную деятельность Компании. Эти показатели, не относящиеся к GAAP, не соответствуют или не являются альтернативой GAAP и могут отличаться от показателей, не относящихся к GAAP, используемых другими компаниями. Ниже в финансовых таблицах, прилагаемых к настоящему пресс-релизу, приведены сверки финансовых показателей, не относящихся к GAAP, с наиболее непосредственно сопоставимыми финансовыми показателями GAAP.
Прогнозные заявленияnuvasive предупреждает вас, что заявления, включенные в этот пресс-релиз или сделанные на телефонной конференции для инвесторов, на которую ссылается здесь, которые не являются описанием исторических фактов, являются прогнозными заявлениями, которые связаны с рисками, неопределенностями, предположениями и другими факторами, которые, если они не оправдаются или не подтвердятся, могут привести к появлению ПСЕВДОНИМОВ_0 результаты будут существенно отличаться от исторических результатов или результатов, выраженных или подразумеваемых в таких прогнозных заявлениях. Кроме того, в этом пресс-релизе содержатся избранные финансовые результаты за первый квартал 2022 года, а также прогнозы на 2022 год, финансовые рекомендации и ожидания относительно долгосрочных финансовых показателей. Результаты Компании за первый квартал 2022 года представлены до завершения процедур проверки и аудита внешними аудиторами Компании и могут быть скорректированы. Кроме того, прогнозы Компании на 2022 финансовый год и ожидания в отношении долгосрочных финансовых показателей представляют собой первоначальные оценки и подвержены риску неточности из-за предварительного характера прогнозов, риска дальнейшей корректировки или непредвиденных трудностей с продажей продуктов или получением ожидаемой прибыльности. Потенциальные риски и неопределенности, которые способствуют неопределенному характеру этих заявлений, включают, среди прочего, влияние пандемии COVID-19 на бизнес и финансовые результаты Компании; способность Компании поддерживать операции для поддержки своих клиентов и пациентов в ближайшей перспективе и извлекать выгоду из будущего роста возможности; риски, связанные с принятием хирургических продуктов и процедур Компании хирургами позвоночника и больницами, разработкой и принятием новых продуктов или улучшений продукта, клинической и статистической проверкой преимуществ, достигнутых за счет использования продуктов NuVasive, способностью Компании адекватно управлять запасами, поскольку она продолжает выпускать новые продукты, ее способность нанимать и удерживать руководство и ключевой персонал, а также другие риски и неопределенности, более подробно описанные в пресс-релизах Компании и периодических заявках в Комиссию по ценным бумагам и биржам. Публичные заявки NuVasive в Комиссию по ценным бумагам и биржам доступны по адресу www.sec.gov . NuVasive не берет на себя никаких обязательств по обновлению любого прогнозного заявления, чтобы отразить события или обстоятельства, возникшие после даты, на которую оно было сделано.
NuVasive, Inc. |
||||
Consolidated Statements of Operations |
||||
(in thousands, except per share data) |
||||
Three Months Ended March 31, |
||||
(unaudited) |
2022 |
2021 |
||
Net sales: |
||||
Products |
$ 265,973 |
$ 245,451 |
||
Services |
24,789 |
25,798 |
||
Total net sales |
290,762 |
271,249 |
||
Cost of sales (excluding below amortization of intangible assets): |
||||
Products |
57,183 |
53,302 |
||
Services |
21,914 |
18,509 |
||
Total cost of sales |
79,097 |
71,811 |
||
Gross profit |
211,665 |
199,438 |
||
Operating expenses: |
||||
Selling, general and administrative |
160,281 |
145,954 |
||
Research and development |
23,358 |
22,224 |
||
Amortization of intangible assets |
13,032 |
13,337 |
||
Business transition costs |
3,060 |
5,584 |
||
Total operating expenses |
199,731 |
187,099 |
||
Interest and other income (expense), net: |
||||
Interest income |
43 |
87 |
||
Interest expense |
(4,379) |
(8,030) |
||
Other income (expense), net |
16,244 |
(12,526) |
||
Total interest and other income (expense), net |
11,908 |
(20,469) |
||
Income (loss) before income taxes |
23,842 |
(8,130) |
||
Income tax (expense) benefit |
(4,641) |
620 |
||
Consolidated net income (loss) |
$ 19,201 |
$ (7,510) |
||
Net income (loss) per share: |
||||
Basic |
$ 0.37 |
$ (0.15) |
||
Diluted |
$ 0.35 |
$ (0.15) |
||
Weighted average shares outstanding: |
||||
Basic |
51,829 |
51,379 |
||
Diluted |
62,579 |
51,379 |
||
NuVasive, Inc. |
||||
Consolidated Balance Sheets |
||||
(in thousands, except par value data) |
||||
March 31, 2022 |
December 31, 2021 |
|||
ASSETS |
(Unaudited) |
|||
Current assets: |
||||
Cash and cash equivalents |
$ 205,312 |
$ 246,091 |
||
Accounts receivable, net of allowances of $20,707 and $21,064, respectively |
231,425 |
214,398 |
||
Inventory, net |
324,403 |
315,845 |
||
Prepaid income taxes |
5,536 |
5,425 |
||
Prepaid expenses and other current assets |
25,538 |
20,665 |
||
Total current assets |
792,214 |
802,424 |
||
Property and equipment, net |
313,689 |
303,664 |
||
Intangible assets, net |
233,301 |
242,675 |
||
Goodwill |
636,703 |
633,467 |
||
Operating lease right-of-use assets |
100,656 |
102,987 |
||
Deferred tax assets |
61,294 |
48,003 |
||
Restricted cash and investments |
1,494 |
1,494 |
||
Other assets |
21,150 |
19,361 |
||
Total assets |
$ 2,160,501 |
$ 2,154,075 |
||
LIABILITIES AND EQUITY |
||||
Current liabilities: |
||||
Accounts payable and accrued liabilities |
$ 115,674 |
$ 115,614 |
||
Contingent consideration liabilities |
66,054 |
7,986 |
||
Accrued payroll and related expenses |
55,848 |
66,596 |
||
Operating lease liabilities |
10,043 |
9,867 |
||
Income tax liabilities |
1,110 |
828 |
||
Total current liabilities |
248,729 |
200,891 |
||
Long-term senior convertible notes |
886,793 |
884,984 |
||
Deferred tax liabilities |
12,807 |
3,049 |
||
Operating lease liabilities |
109,093 |
111,592 |
||
Contingent consideration liabilities |
73,762 |
139,824 |
||
Other long-term liabilities |
17,396 |
18,528 |
||
Commitments and contingencies |
||||
Stockholders' equity: |
||||
Preferred stock, $0.001 par value; 5,000 shares authorized, none outstanding |
— |
— |
||
Common stock, $0.001 par value; 150,000 shares authorized at March 31, 2022 and |
63 |
63 |
||
Additional paid-in capital |
1,441,783 |
1,434,976 |
||
Accumulated other comprehensive loss |
(11,741) |
(7,792) |
||
Retained earnings |
64,909 |
45,708 |
||
Treasury stock at cost; 6,798 shares and 6,700 shares at March 31, 2022 and |
(683,093) |
(677,748) |
||
Total equity |
811,921 |
795,207 |
||
Total liabilities and equity |
$ 2,160,501 |
$ 2,154,075 |
||
NuVasive, Inc. |
||||
Consolidated Statements of Cash Flows |
||||
(in thousands) |
||||
Three Months Ended March 31, |
||||
(unaudited) |
2022 |
2021 |
||
Operating activities: |
||||
Consolidated net income (loss) |
$ 19,201 |
$ (7,510) |
||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||
Depreciation and amortization |
36,801 |
36,432 |
||
Deferred income taxes |
(3,891) |
(3,535) |
||
Amortization of non-cash interest |
1,963 |
2,660 |
||
Stock-based compensation |
6,807 |
7,709 |
||
Net (gain) loss from foreign currency adjustments |
(15,988) |
12,547 |
||
Reserves on current assets |
(1,864) |
4,002 |
||
Other non-cash adjustments |
1,365 |
6,397 |
||
Changes in operating assets and liabilities, net of effects from acquisitions: |
||||
Accounts receivable |
(17,216) |
(1,544) |
||
Inventory |
(3,215) |
(12,464) |
||
Prepaid expenses and other current assets |
805 |
(2,057) |
||
Accounts payable and accrued liabilities |
(7,956) |
(5,663) |
||
Accrued payroll and related expenses |
(10,491) |
(4,271) |
||
Income taxes |
218 |
(1,064) |
||
Net cash provided by operating activities |
6,539 |
31,639 |
||
Investing activities: |
||||
Acquisition of Simplify Medical, net of cash acquired |
— |
(149,408) |
||
Purchases of intangible assets |
— |
(1,200) |
||
Purchases of property and equipment |
(33,223) |
(25,070) |
||
Proceeds from sales of marketable securities |
— |
127,023 |
||
Proceeds from maturities of marketable securities |
— |
46,000 |
||
Other investing activities |
(947) |
— |
||
Net cash used in investing activities |
(34,170) |
(2,655) |
||
Financing activities: |
||||
Payment of contingent consideration |
(6,839) |
(3) |
||
Purchases of treasury stock |
(5,345) |
(55) |
||
Payments upon settlement of senior convertible notes |
— |
(649,426) |
||
Other financing activities |
(521) |
(341) |
||
Net cash used in financing activities |
(12,705) |
(649,825) |
||
Effect of exchange rate changes on cash |
(443) |
(2,171) |
||
Decrease in cash, cash equivalents and restricted cash |
(40,779) |
(623,012) |
||
Cash, cash equivalents and restricted cash at beginning of period |
247,585 |
858,363 |
||
Cash, cash equivalents and restricted cash at end of period |
$ 206,806 |
$ 235,351 |
||
For the Three Months Ended March 31, 2022 |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(Unaudited - in thousands, except per share data) |
|||||||
Gross Profit |
Operating |
Net Income |
Diluted |
Diluted |
Net Income |
||
Reported GAAP |
$ 211,665 |
$ 11,934 |
$ 19,201 |
$ 0.35 |
62,579 |
$ 19,201 |
|
% of net sales |
72.8% |
4.1% |
|||||
Non-cash purchase accounting adjustments on acquisitions1 |
557 |
557 |
557 |
557 |
|||
Amortization of intangible assets |
13,032 |
13,032 |
|||||
Litigation related expenses and settlements2 |
3,201 |
3,201 |
3,201 |
||||
Business transition costs3 |
3,060 |
3,060 |
3,060 |
||||
European medical device regulation4 |
2,191 |
2,191 |
2,191 |
||||
Non-cash acquisition-related foreign currency impacts5 |
(9,318) |
(9,318) |
|||||
Tax effect of adjustments6 |
(3,768) |
||||||
Interest expense/(income), net |
4,336 |
||||||
Income tax expense |
4,641 |
||||||
Depreciation and amortization |
36,801 |
||||||
Non-cash stock-based compensation |
6,807 |
||||||
Adjusted Non-GAAP |
$ 212,222 |
$ 33,975 |
$ 28,156 |
$ 0.54 |
52,410 |
$ 71,477 |
|
% of net sales |
73.0% |
11.7% |
24.6% |
||||
1 |
Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized |
||||||
2 |
Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property. |
||||||
3 |
Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party |
||||||
4 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical |
||||||
5 |
Represents non-cash adjustments to acquisition-related intercompany balances and contingent consideration liabilities held in a foreign currency. |
||||||
6 |
Represents the impact from tax affecting the adjustments above at their statutory tax rate. |
||||||
7 |
GAAP diluted EPS includes the dilutive impact of applying the if-converted method to the Company's convertible notes. Adjusted non-GAAP diluted WASO |
||||||
For the Three Months Ended March 31, 2021 |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(Unaudited - in thousands, except per share data) |
|||||||
Gross |
Operating |
Net (Loss) |
Diluted |
Diluted |
Net (Loss) to |
||
Reported GAAP |
$ 199,438 |
$ 12,339 |
$ (7,510) |
$ (0.15) |
51,379 |
$ (7,510) |
|
% of net sales |
73.5% |
4.5% |
|||||
Non-cash purchase accounting adjustments on acquisitions1 |
186 |
186 |
186 |
186 |
|||
Amortization of intangible assets |
13,337 |
13,337 |
|||||
Litigation related expenses and settlements2 |
1,961 |
1,961 |
1,961 |
||||
Business transition costs3 |
5,584 |
5,584 |
5,584 |
||||
European medical device regulation4 |
1,875 |
1,875 |
1,875 |
||||
Non-cash acquisition-related foreign currency impacts5 |
9,848 |
9,848 |
|||||
Tax effect of adjustments6 |
(6,251) |
||||||
Interest expense/(income), net |
7,943 |
||||||
Income tax benefit |
(620) |
||||||
Depreciation and amortization |
36,432 |
||||||
Non-cash stock-based compensation |
7,709 |
||||||
Adjusted Non-GAAP |
$ 199,624 |
$ 35,282 |
$ 19,030 |
$ 0.37 |
52,069 |
$ 63,408 |
|
% of net sales |
73.6% |
13.0% |
23.4% |
||||
1 |
Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized |
||||||
2 |
Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property. |
||||||
3 |
Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party |
||||||
4 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical |
||||||
5 |
Represents non-cash adjustments to acquisition-related intercompany balances and contingent consideration liabilities held in a foreign currency. |
||||||
6 |
Represents the impact from tax affecting the adjustments above at their statutory tax rate. |
||||||
7 |
GAAP diluted EPS includes the dilutive impact of applying the if-converted method to the Company's convertible notes. Adjusted non-GAAP diluted WASO |
||||||
Full Year 2022 Financial Guidance |
|||||||
Reconciliation of GAAP to Non-GAAP EPS |
|||||||
2022 Guidance Range1, 2 |
|||||||
2021 Actuals1 |
Prior |
Current |
|||||
GAAP diluted earnings (loss) per share |
$(1.24) |
$0.71-1.01 |
$1.05-1.35 |
||||
Impact of dilution3 |
0.02 |
~0.15 |
~0.05 |
||||
Amortization of intangible assets |
1.10 |
~1.05 |
~1.00 |
||||
European medical device regulation4 |
0.16 |
~0.30 |
~0.30 |
||||
Inventory charges associated with product withdrawal5 |
0.27 |
- |
- |
||||
Other6 |
1.83 |
~0.14 |
~0.05 |
||||
Tax effect of adjustments7 |
(0.45) |
~(0.30) |
~(0.30) |
||||
Non-GAAP diluted earnings per share |
$1.68 |
$2.05-2.35 |
$2.15-2.45 |
||||
1 |
Data has been intentionally rounded and may not sum. |
||||||
2 |
Prior guidance reflects the range provided February 23, 2022. Current guidance reflects the range provided May 4, 2022. |
||||||
3 |
GAAP diluted EPS includes the dilutive impact of applying the if-converted method to the Company's convertible notes. Adjusted non-GAAP diluted |
||||||
4 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European |
||||||
5 |
Represents charges for inventory write-offs associated with the Company's product withdrawals. During the third quarter of 2021, the Company made a |
||||||
6 |
Includes costs primarily associated with litigation related expenses and settlements, non-cash acquisition-related foreign currency impacts, non-cash |
||||||
7 |
Represents the impact from tax affecting the adjustments above at their statutory tax rate. |
||||||
Full Year 2022 Financial Guidance |
||||||||
Reconciliation of GAAP to Non-GAAP Operating Margin % |
||||||||
2022 Guidance Range1, 2 |
||||||||
2021 Actuals1 |
Prior |
Current |
||||||
GAAP Operating Margin % |
(1.1%) |
6.7%-8.2% |
6.3%-7.8% |
|||||
Amortization of intangible assets |
5.0% |
~4.5% |
~4.4% |
|||||
European medical device regulation3 |
0.7% |
~1.3% |
~1.3% |
|||||
Inventory charges associated with product withdrawal4 |
1.3% |
- |
- |
|||||
Other 5 |
6.8% |
~0.5% |
~1.0% |
|||||
Non-GAAP Operating Margin % |
12.8% |
13.0%-14.5% |
13.0%-14.5% |
|||||
1 |
Data has been intentionally rounded and may not sum. |
|||||||
2 |
Prior guidance reflects the range provided February 23, 2022. Current guidance reflects the range provided May 4, 2022. |
|||||||
3 |
Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with |
|||||||
4 |
Represents charges for inventory write-offs associated with the Company's product withdrawals. During the third quarter of 2021, the |
|||||||
5 |
Includes costs primarily associated with litigation related expenses and settlements, non-cash purchase accounting adjustments on |
|||||||
ИСТОЧНИК NuVasive, Inc.
Показать большеПоказать меньше
